Evidence map›Paper›PMID 34345932›Full record

ReviewCurrent atherosclerosis reports2021

Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?

Arrigo F G Cicero, Federica Fogacci, Anca Pantea Stoian, Michal Vrablik, Khalid Al Rasadi, Maciej Banach, Peter P Toth, Manfredi Rizzo

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current atherosclerosis reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06045377 (Effect of a Nutraceutical, Containing Red Yeast Rice and Polycosanols), which is not on this map. Cited by 55 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06045377 nacompletednot on this map

Effect of a Nutraceutical, Containing Red Yeast Rice and Polycosanols (Armolipid), on Lipid Profile in Children With Moderate and Severe Hypercholesterolemia.

TypeinterventionalSponsorAthens General Children's Hospital "Pan. & Aglaia Kyriakou"Ran2020 to 2022Enrolled90ConditionsDyslipidemias, Children, OnlyArmsEffect of Armolipid on Lipid Profile in Children With Hypercholesterolemia
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Frontiers in nutrition · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Arrigo F G CiceroDepartment of Medicine and Surgery Sciences, University of Bologna, Bologna, Italy. arrigo.cicero@unibo.it.ORCID 0000-0002-4367-3884
Federica FogacciDepartment of Medicine and Surgery Sciences, University of Bologna, Bologna, Italy.
Anca Pantea StoianFaculty of Medicine, Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Michal VrablikThird Department of Internal Medicine, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
Khalid Al RasadiMedical Research Centre, Sultan Qaboos University, Muscat, Oman.
Maciej BanachDepartment of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Łódź, Poland.
Peter P TothCGH Medical Center, Sterling, IL, USA.
Manfredi RizzoItalian Society of Nutraceuticals (SINut), Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe aim of this review is to summarize the available clinical efficacy and safety data related to the most studied and used lipid-lowering nutraceuticals. RECENT

findingsA growing number of meta-analyses of randomized clinical trials supports the effectiveness and tolerability of some lipid-lowering nutraceuticals such as red yeast rice, plant sterols and stanols, soluble fibers, berberine, artichoke extracts, bergamot polyphenol fraction, garlic, green tea, and spiruline. No significant safety concern has been raised for the use of such products. Association of more lipid-lowering nutraceuticals and of some nutraceuticals with lipid-lowering drugs has been tested as well. Current evidence suggests that some clinically tested lipid-lowering nutraceuticals could be safely used to improve plasma lipid levels in subjects affected by mild-to-moderate dyslipidaemia with low cardiovascular risk.

Indexed as

DyslipidemiasPhytosterolsDietary SupplementsHumansHypolipidemic AgentsLipidsHypolipidemic AgentsLipidsPhytosterolsCholesterolDietary supplementsEfficacyLow-density lipoproteinsNutraceuticalsSafety

Identifiers

PMID34345932
PMCPMC8332568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.